The pharmaceutical landscape for Endocrinology Drugs, particularly those based on complex peptides and proteins, is being increasingly shaped by the introduction of biosimilars and generics. This development is crucial for expanding global access to essential treatments. Key areas affected include insulin analogues and human growth hormone (hGH). As patents expire on originator biologicals,...